2. Academic Validation
  3. Therapeutic options in peripheral T cell lymphoma

Therapeutic options in peripheral T cell lymphoma

  • J Hematol Oncol. 2016 Apr 12;9:37. doi: 10.1186/s13045-016-0267-0.
Yaping Zhang 1 2,  Wei Xu 3,  Hong Liu 4,  Jianyong Li 5 6
Affiliations

Affiliations

  • 1 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. [email protected].
  • 2 Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226000, China. [email protected].
  • 3 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. [email protected].
  • 4 Department of Hematology, Affiliated Hospital of Nantong University, Nantong, 226000, China.
  • 5 Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
  • 6 Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University, Nanjing, 210029, China.
PMID: 27071634 DOI: 10.1186/s13045-016-0267-0
Abstract

Peripheral T cell lymphoma (PTCL) is a rare and heterogeneous group of non-Hodgkin lymphomas with a very poor prognosis. The standard first-line treatments have resulted in unsatisfactory patient outcomes. With the exception of low-risk anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL), the majority of patients relapse rapidly; the current 5-year overall survival rates are only 10-30%. Novel targeted therapies and combination chemotherapies are required for the treatment of patients with PTCL. In recent years, some retrospective and prospective studies have been performed concerning PTCL. Consequently, a number of novel agents and their relevant combination therapies have been identified, including histone deacetylase inhibitors, immunoconjugates, antifolates, monoclonal Antibodies, immunomodulatory agents, nucleoside analogs, Proteasome inhibitors, kinase inhibitors, bendamustine, L-asparaginase, and other targeted agents. It is hoped that these innovative approaches will finally improve outcomes in patients with PTCL. This review summarizes the currently available approaches for the treatment of PTCL with an emphasis on potential new agents, including the role of stem cell transplantation.

Keywords

Novel target; Peripheral T cell lymphoma; Therapy.

Figures